Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.53 |
| ▸ | HAO1 | Q9UJM8 | 2/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.51 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.51 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | STAT3 | P40763 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21656839 | 1.00 | KMO (0.53) | KMOHAO1HDAC8HDAC6PARP15 | |
| SCHEMBL21656947 | 0.98 | PARP10 (0.53) | KMOHAO1HDAC8HDAC6PARP15 | |
| SCHEMBL21656804 | 0.95 | PARP10 (0.53) | KMOHAO1HDAC8HDAC6PARP15 | |
| SCHEMBL21274803 | 0.91 | PARP10 (0.56) | HDAC8HDAC6PARP15PARP10HDAC1 | |
| SCHEMBL31003815 | 0.90 | KMO (0.54) | KMOHAO1PARP15PARP10SRD5A2 | |
| SCHEMBL354930 | 0.89 | KMO (0.62) | KMOHAO1HDAC8HDAC6HDAC1 | |
| SCHEMBL22291720 | 0.89 | KMO (0.62) | KMOHAO1HDAC8HDAC6HDAC1 | |
| Bicarbonate SCHEMBL7018415 | 0.88 | KMO (0.61) | KMOHAO1HDAC8HDAC6HDAC1 | |
| SCHEMBL3495930 | 0.88 | HDAC8 (0.63) | KMOHAO1HDAC8HDAC6HDAC1 | |
| SCHEMBL21628450 | 0.85 | PARP10 (0.61) | HDAC8HDAC6PARP15PARP10HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3429576-B1 | ENHANCERS OF NOTCH SIGNALING AND THEIR USE IN THE TREATMENT OF CANCERS AND MALIGNANCIES MEDICABLE BY UPREGULATION OF NOTCH | Xeniopro GmbH (DE) | 2025-10-29 | — | — | EP | disclosed |
| CN-119954697-A | Aromatic molecules for the treatment of pathological conditions | 赛尼欧普罗有限责任公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-119930483-A | Aromatic molecules for the treatment of pathological conditions | 赛尼欧普罗有限责任公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-118290322-A | Aromatic molecules for the treatment of pathological conditions | 赛尼欧普罗有限责任公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20220354949-A1 | NOVEL COMPOUNDS | Xeniopro GmbH (DE) | 2022-11-10 | — | — | US | disclosed |
| EP-3840834-A2 | AROMATIC MOLECULES FOR USE IN THE TREATMENT OF PATHOLOGICAL CONDITIONS | Xeniopro GmbH (DE) | 2021-06-30 | — | — | EP | disclosed |
| CN-112888479-A | Aromatic molecules for the treatment of pathological conditions | 赛尼欧普罗有限责任公司 | 2021-06-01 | — | — | CN | disclosed |
| US-20200360355-A1 | ENHANCERS OF NOTCH SIGNALING AND THEIR USE THEREOF IN THE TREATMENT OF CANCERS AND MALIGNANCIES MEDICABLE BY UPREGULATION OF NOTCH | Xeniopro GmbH (DE) | 2020-11-19 | — | — | US | disclosed |
| US-20200360355-A1 | ENHANCERS OF NOTCH SIGNALING AND THEIR USE THEREOF IN THE TREATMENT OF CANCERS AND MALIGNANCIES MEDICABLE BY UPREGULATION OF NOTCH | Xeniopro GmbH (DE) | 2020-11-19 | — | — | US | disclosed |
| US-10772876-B2 | Enhancers of Notch signaling and the use thereof in the treatment of cancers and malignancies medicable by upregulation of Notch | Xeniopro GmbH (DE) | 2020-09-15 | — | — | US | disclosed |
| US-10772876-B2 | Enhancers of Notch signaling and the use thereof in the treatment of cancers and malignancies medicable by upregulation of Notch | Xeniopro GmbH (DE) | 2020-09-15 | — | — | US | disclosed |
| WO-2020039088-A2 | NOVEL COMPOUNDS | Xeniopro GmbH (DE) | 2020-02-27 | — | — | WO | disclosed |
| US-20190083476-A1 | ENHANCERS OF NOTCH SIGNALING AND THE USE THEREOF IN THE TREATMENT OF CANCERS AND MALIGNANCIES MEDICABLE BY UPREGULATION OF NOTCH | Xeniopro GmbH (DE) | 2019-03-21 | — | — | US | disclosed |
| US-20190083476-A1 | ENHANCERS OF NOTCH SIGNALING AND THE USE THEREOF IN THE TREATMENT OF CANCERS AND MALIGNANCIES MEDICABLE BY UPREGULATION OF NOTCH | Xeniopro GmbH (DE) | 2019-03-21 | — | — | US | disclosed |
| WO-2017158190-A1 | ENHANCERS OF NOTCH SIGNALING AND THEIR USE IN THE TREATMENT OF CANCERS AND MALIGNANCIES MEDICABLE BY UPREGULATION OF NOTCH | Ecole polytechnique fédérale de Lausanne (EPFL) (CH) | 2017-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220354949-A1 | NOVEL COMPOUNDS | MUSK, TYR, IKZF3 | KMO 392/4885HAO1 2538/4885HDAC8 1020/4885 |
| US-10772876-B2 | Enhancers of Notch signaling and the use thereof in the treatment of cancers and malignancies medicable by upregulation of Notch | NOTCH1, DNER, NOTCH4 | KMO 2678/4885HAO1 4800/4885HDAC8 3000/4885 |
| US-20200360355-A1 | ENHANCERS OF NOTCH SIGNALING AND THEIR USE THEREOF IN THE TREATMENT OF CANCERS AND MALIGNANCIES MEDICABLE BY UPREGULATION OF NOTCH | NOTCH1, DNER, NOTCH4 | KMO 2754/4885HAO1 4806/4885HDAC8 2901/4885 |
| US-20190083476-A1 | ENHANCERS OF NOTCH SIGNALING AND THE USE THEREOF IN THE TREATMENT OF CANCERS AND MALIGNANCIES MEDICABLE BY UPREGULATION OF NOTCH | NOTCH1, DNER, NOTCH4 | KMO 2678/4885HAO1 4800/4885HDAC8 3000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.